Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07870746 |
| Title | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC (LUTEON ATLAS) |
| Acronym | LUTEON ATLAS |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Telix Pharmaceuticals (Innovations) Pty Limited |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |